Telesis Bio (TBIO) Stock Price, News & Analysis

Company Overview

Telesis Bio, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel immunotherapies that harness the body’s innate immune system. The company’s proprietary platform designs small-molecule and biologic agonists of pattern recognition receptors (PRRs), including toll-like receptors (TLRs) and NOD-like receptors, to stimulate targeted immune responses. Telesis Bio’s lead programs are advancing through preclinical and early clinical development in immuno-oncology and vaccine adjuvant applications.

The company’s pipeline includes synthetic pathogen-associated molecular patterns (PAMPs) that are engineered to act as immune stimulants. These agents are being evaluated both as monotherapies in solid tumors and in combination with checkpoint inhibitors, with the goal of converting immunologically “cold” tumors into “hot” ones that are more likely to respond to treatment. In parallel, Telesis Bio is exploring the use of its PRR agonists as adjuvants in therapeutic and prophylactic vaccines, aiming to improve antigen-specific immune activation.

Founded in 2015 and headquartered in South San Francisco, California, Telesis Bio collaborates with leading academic institutions and biotechnology partners to accelerate its research and development efforts. The company is led by an experienced management team with expertise in immunology, molecular biology, and clinical development. Telesis Bio continues to expand its platform through strategic partnerships and preclinical studies, with the objective of delivering next-generation immunotherapies to patients in the United States and globally.

Key Stats

• Today's Range: $0.0010 to $0.0010
• 50-Day Range: $0.00 to $0.30
• 52-Week Range: $0.00 to $5.17
• Volume: 157 shs
• Average Volume: 6,114 shs
• Market Capitalization: $1.80 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Telesis Bio Stock Analysis - MarketRank™

Telesis Bio scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Telesis Bio.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Telesis Bio is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Telesis Bio is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Telesis Bio has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.03% of the float of Telesis Bio has been sold short.

Short Interest Ratio / Days to Cover

Telesis Bio has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Telesis Bio has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Telesis Bio does not currently pay a dividend.

Dividend Growth

Telesis Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.03% of the float of Telesis Bio has been sold short.

Short Interest Ratio / Days to Cover

Telesis Bio has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Telesis Bio has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Telesis Bio has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Telesis Bio this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Telesis Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.50% of the stock of Telesis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 37.63% of the stock of Telesis Bio is held by institutions.

TBIO Stock Analysis - Frequently Asked Questions

How have TBIO shares performed this year?

Telesis Bio's stock was trading at $0.40 at the beginning of the year. Since then, TBIO shares have decreased by 99.8% and is now trading at $0.0010.

How were Telesis Bio's earnings last quarter?

Telesis Bio, Inc. (NASDAQ:TBIO) issued its quarterly earnings results on Monday, November, 8th. The company reported ($6.12) EPS for the quarter, missing analysts' consensus estimates of ($5.04) by $1.08. The firm had revenue of $2.79 million for the quarter, compared to analysts' expectations of $2.93 million.

When did Telesis Bio's stock split?

Telesis Bio shares reverse split on Thursday, May 9th 2024.The 1-18 reverse split was announced on Thursday, May 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did Telesis Bio IPO?

Telesis Bio (TBIO) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.

How do I buy shares of Telesis Bio?

Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Telesis Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Telesis Bio investors own include Ford Motor (F), Pfizer (PFE), PayPal (PYPL), SoFi Technologies (SOFI), Plug Power (PLUG) and XPeng (XPEV).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 9/16/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:TBIO
• Previous Symbol: NASDAQ:DNAY
• CIK: 1850079
• Web: telesisbio.com
• Phone: 858-228-4115
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($28.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.72 million
• Net Margins: -336.59%
• Pretax Margin: -334.81%
• Return on Equity: N/A
• Return on Assets: -61.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.06

Sales & Book Value

• Annual Sales: $225.09 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.14 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 1,802,000
• Free Float: 1,360,000
• Market Cap: $1.80 thousand
• Optionable: Optionable
• Beta: 2.73